TY - JOUR
T1 - The use of a non-specific defence mechanism inducer in calves exposed to bovine herpesvirus-1 infection
T2 - Preliminary trials
AU - Castrucci, G.
AU - Ferrari, M.
AU - Osburn, Bennie
AU - Frigeri, F.
AU - Barreca, F.
AU - Tagliati, S.
AU - Cuteri, V.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - The efficacy of an immunomodulator, the Baypamun (Bayer AG), was tested in calves which were subsequently exposed to bovine herpesvirus-1 (BHV-1) infection. Two groups of calves, of 8 animals each, were used for two trials. In one trial, 4 calves were treated with the immunomodulator and the remaining 4 were left as untreated controls. Two hours after the first injection of Baypamun, all calves, i.e. the treated and the untreated ones, were challenged with BHV-1. Comparing them to the untreated controls, the calves which were given the immunomodulator developed milder signs of the disease and shed a significantly lower concentration of virus. In the second experiment, 4 calves were given Baypamun and 4 calves were not, as above, but they were not inoculated with BHV-1; however, they were housed together with the calves of the former group (experimentally infected with BHV-1). The 8 calves all became infected but those that had been treated with Baypamun did not show any clinical signs of the disease, whereas the untreated calves underwent a clinical response which was considered to be typical of BHV-1 respiratory infection, as usually seen under natural conditions. In this case the shedding of virus by the calves treated with the immunomodulator also underwent a significant reduction.
AB - The efficacy of an immunomodulator, the Baypamun (Bayer AG), was tested in calves which were subsequently exposed to bovine herpesvirus-1 (BHV-1) infection. Two groups of calves, of 8 animals each, were used for two trials. In one trial, 4 calves were treated with the immunomodulator and the remaining 4 were left as untreated controls. Two hours after the first injection of Baypamun, all calves, i.e. the treated and the untreated ones, were challenged with BHV-1. Comparing them to the untreated controls, the calves which were given the immunomodulator developed milder signs of the disease and shed a significantly lower concentration of virus. In the second experiment, 4 calves were given Baypamun and 4 calves were not, as above, but they were not inoculated with BHV-1; however, they were housed together with the calves of the former group (experimentally infected with BHV-1). The 8 calves all became infected but those that had been treated with Baypamun did not show any clinical signs of the disease, whereas the untreated calves underwent a clinical response which was considered to be typical of BHV-1 respiratory infection, as usually seen under natural conditions. In this case the shedding of virus by the calves treated with the immunomodulator also underwent a significant reduction.
KW - bovine herpesvirus-1
KW - calves
KW - Immunomodulator
UR - http://www.scopus.com/inward/record.url?scp=0028934167&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028934167&partnerID=8YFLogxK
U2 - 10.1016/0147-9571(95)98849-D
DO - 10.1016/0147-9571(95)98849-D
M3 - Article
C2 - 7621672
AN - SCOPUS:0028934167
VL - 18
SP - 85
EP - 91
JO - Comparative Immunology, Microbiology and Infectious Diseases
JF - Comparative Immunology, Microbiology and Infectious Diseases
SN - 0147-9571
IS - 2
ER -